Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
OnKure Therapeutics, Inc. is the issuer of Class A common stock covered in this beneficial ownership report. Investment adviser ADAR1 Capital Management, LLC and its manager Daniel Schneeberger each report beneficial ownership of 2,238,684 shares of Class A common stock, representing 5.5% of the class based on 40,496,309 shares outstanding as of June 30, 2026. These shares include holdings by ADAR1 Partners, LP, Spearhead Insurance Solutions IDF, LLC, and other separately managed accounts for which ADAR1 Capital Management acts as investment manager or sub-adviser.
ADAR1 Capital Management GP, LLC, as general partner of ADAR1 Partners, LP, reports beneficial ownership of 1,832,117 shares, or 4.5% of the class, and this amendment is identified as an exit filing solely for ADAR1 Capital Management GP, LLC as a 5% owner. All reporting persons disclose shared voting and dispositive power over their reported shares and no sole voting or dispositive power.
Key Figures
ADAR1 Capital Management beneficial ownership:2,238,684 shares (5.5%)ADAR1 Capital Management GP, LLC beneficial ownership:1,832,117 shares (4.5%)Daniel Schneeberger beneficial ownership:2,238,684 shares (5.5%)+4 more
7 metrics
ADAR1 Capital Management beneficial ownership2,238,684 shares (5.5%)Class A common stock of OnKure Therapeutics based on 40,496,309 shares outstanding as of June 30, 2026
ADAR1 Capital Management GP, LLC beneficial ownership1,832,117 shares (4.5%)Class A common stock of OnKure Therapeutics through ADAR1 Partners, LP as of June 30, 2026
Daniel Schneeberger beneficial ownership2,238,684 shares (5.5%)Indirect ownership via ADAR1 Capital Management entities and managed accounts as of June 30, 2026
Shares outstanding baseline40,496,309 sharesOnKure Therapeutics Class A common stock outstanding as of June 30, 2026 per Form 10-Q
ADAR1 Partners, LP holdings1,832,117 sharesClass A common stock held by ADAR1 Partners, LP included in reported positions as of June 30, 2026
Spearhead Insurance Solutions IDF, LLC holdings299,150 sharesClass A common stock included in ADAR1 Capital Management and Schneeberger beneficial ownership
Other separately managed accounts holdings107,417 sharesClass A common stock in accounts managed by ADAR1 Capital Management as of June 30, 2026
"may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP"
Beneficially own means having the economic rights and risks of a security—such as the right to receive dividends, sell the shares, or profit from price changes—whether or not your name appears on the official share register. Think of it like renting a car: you use it and reap the benefits even if the title lists someone else. Investors care because beneficial ownership determines who truly controls value, must be disclosed under securities rules, and can signal potential influence or trading activity that affects a stock’s price.
shared voting powerfinancial
"Shared Voting Power 2,238,684.00"
Shared voting power occurs when two or more parties jointly have the right to vote or decide how a block of company shares is cast, like co-owners who must agree before moving a piece of furniture. Investors care because who controls voting rights affects board elections, major corporate decisions and takeover outcomes, and shared control can alter regulatory disclosures and the practical influence any holder has over a company’s direction and value.
shared dispositive powerfinancial
"Shared Dispositive Power 2,238,684.00"
exit filingregulatory
"this filing is an exit filing solely for ADAR1 General Partner"
control personregulatory
"Mr. Schneeberger is filing this as a control person in respect of shares"
A control person is an individual or entity that can significantly influence a company’s decisions and direction through ownership, voting power, or contractual rights—think of them as the captain who can steer the ship. Investors care because a control person’s choices affect corporate strategy, board appointments, and transactions that can raise or lower a stock’s value, and they often carry additional legal responsibilities and disclosure requirements to protect other shareholders.
investment adviserfinancial
"ADAR1 Capital Management, an investment adviser as described in SS 240.13d-1(b)(1)(ii)(E)"
An investment adviser is a person or firm that professionally manages money and gives recommendations about buying, selling, or holding investments. Like a financial coach or guide, they have a legal duty to act in a client's best financial interest, so their advice, fees and potential conflicts can directly affect returns and risk — making their role important for investors who want informed, accountable help with portfolios.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What percentage of OnKure Therapeutics (OKUR) does ADAR1 Capital Management report owning?
ADAR1 Capital Management, LLC reports beneficial ownership of 2,238,684 shares of OnKure Therapeutics Class A common stock, representing 5.5% of the outstanding class, based on 40,496,309 shares outstanding as of June 30, 2026.
How many OnKure Therapeutics (OKUR) shares does ADAR1 Capital Management GP, LLC beneficially own?
ADAR1 Capital Management GP, LLC reports beneficial ownership of 1,832,117 shares of OnKure Therapeutics Class A common stock, representing 4.5% of the class, through its role as general partner of ADAR1 Partners, LP as of June 30, 2026.
What is Daniel Schneeberger’s reported beneficial ownership in OnKure Therapeutics (OKUR)?
Daniel Schneeberger reports beneficial ownership of 2,238,684 shares of OnKure Therapeutics Class A common stock, equal to 5.5% of the outstanding shares, through his managerial roles over ADAR1 Capital Management entities and related managed accounts.
Why is this Schedule 13G/A significant for ADAR1 Capital Management GP, LLC and OnKure Therapeutics (OKUR)?
The amendment is designated as an exit filing solely for ADAR1 Capital Management GP, LLC, which now reports 4.5% beneficial ownership, indicating its holdings are below the 5% threshold that typically triggers Schedule 13G reporting.
What is the total number of OnKure Therapeutics (OKUR) shares outstanding used for these ownership calculations?
The reported ownership percentages are calculated using 40,496,309 shares of OnKure Therapeutics Class A common stock outstanding as of June 30, 2026, as disclosed in the company’s Form 10-Q for that period.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No. 2)
OnKure Therapeutics, Inc.
(Name of Issuer)
Class A Common Stock, par value $0.0001 per share
(Title of Class of Securities)
68277Q105
(CUSIP Number)
06/30/2026
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
schemaVersion:
SCHEDULE 13G
CUSIP Number(s):
68277Q105
1
Names of Reporting Persons
ADAR1 Capital Management, LLC
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
TEXAS
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
2,238,684.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
2,238,684.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
2,238,684.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
5.5 %
12
Type of Reporting Person (See Instructions)
IA, OO
Comment for Type of Reporting Person: Includes (i) 1,832,117 shares of Class A common stock, par value $0.0001 per share ("Common Stock") held by ADAR1 Partners, LP, (ii) 299,150 shares of Common Stock held by Spearhead Insurance Solutions IDF, LLC and (iii) 107,417 shares of Common Stock held by other separately managed accounts as of June 30, 2026. As the investment manager of ADAR1 Partners, LP and as the sub-advisor of Spearhead Insurance Solutions IDF, LLC and the separately managed accounts referenced above, ADAR1 Capital Management, LLC may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP, Spearhead Insurance Solutions IDF, LLC and the separately managed accounts.
Based on 40,496,309 shares of Common Stock of OnKure Therapeutics, Inc. (the "Issuer") outstanding as of June 30, 2026, reported in the Issuer's Form 10-Q for the quarterly period ended June 30, 2026, filed with the Securities and Exchange Commission on August 4, 2026.
SCHEDULE 13G
CUSIP Number(s):
68277Q105
1
Names of Reporting Persons
ADAR1 Capital Management GP, LLC
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
TEXAS
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
1,832,117.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
1,832,117.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
1,832,117.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
4.5 %
12
Type of Reporting Person (See Instructions)
OO
Comment for Type of Reporting Person: Includes 1,832,117 shares of Class A common stock, par value $0.0001 per share ("Common Stock") held by ADAR1 Partners, LP as of June 30, 2026. As the general partner of ADAR1 Partners, LP, ADAR1 Capital Management GP, LLC may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP.
Based on 40,496,309 shares of Common Stock of OnKure Therapeutics, Inc. (the "Issuer") outstanding as of June 30, 2026, reported in the Issuer's Form 10-Q for the quarterly period ended June 30, 2026, filed with the Securities and Exchange Commission on August 4, 2026.
SCHEDULE 13G
CUSIP Number(s):
68277Q105
1
Names of Reporting Persons
Daniel Schneeberger
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
TEXAS
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
2,238,684.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
2,238,684.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
2,238,684.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
5.5 %
12
Type of Reporting Person (See Instructions)
HC, IN
Comment for Type of Reporting Person: Includes (i) 1,832,117 shares of Class A common stock, par value $0.0001 per share ("Common Stock") held by ADAR1 Partners, LP, (ii) 299,150 shares of Common Stock held by Spearhead Insurance Solutions IDF, LLC and (iii) 107,417 shares of Common Stock held by other separately managed accounts as of June 30, 2026. As the manager of ADAR1 Capital Management, LLC, and ADAR1 Capital Management GP, LLC, Mr. Schneeberger may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP, Spearhead Insurance Solutions IDF, LLC and the separately managed accounts referenced above.
Based on 40,496,309 shares of Common Stock of OnKure Therapeutics, Inc. (the "Issuer") outstanding as of June 30, 2026, reported in the Issuer's Form 10-Q for the quarterly period ended June 30, 2026, filed with the Securities and Exchange Commission on August 4, 2026.
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
OnKure Therapeutics, Inc.
(b)
Address of issuer's principal executive offices:
6707 Winchester Circle Suite 400, Boulder, CO 80301
Item 2.
(a)
Name of person filing:
This Schedule is being filed on behalf of each of the following persons (each, a "Reporting Person" and collectively, the "Reporting Persons"):
(i) ADAR1 Capital Management, LLC ("ADAR1 Capital Management");
(ii) ADAR1 Capital Management GP, LLC ("ADAR1 General Partner"); and
(iii) Daniel Schneeberger ("Mr. Schneeberger").
Pursuant to Item 5 below, this filing is an exit filing solely for ADAR1 General Partner.
(b)
Address or principal business office or, if none, residence:
The address of the principal business office of each of the Reporting Persons is 3503 Wild Cherry Drive, Building 9, Austin, Texas 78738.
(c)
Citizenship:
(i) ADAR1 Capital Management is a Texas limited liability company;
(ii) ADAR1 General Partner is a Texas limited liability company; and
(iii) Mr. Schneeberger is a citizen of Switzerland.
(d)
Title of class of securities:
Class A Common Stock, par value $0.0001 per share
(e)
CUSIP No.:
68277Q105
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
The information contained on the cover pages of this Schedule 13G is incorporated herein by reference.
(b)
Percent of class:
The information contained on the cover pages of this Schedule 13G is incorporated herein by reference.
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
The information contained on the cover pages of this Schedule 13G is incorporated herein by reference.
(ii) Shared power to vote or to direct the vote:
The information contained on the cover pages of this Schedule 13G is incorporated herein by reference.
(iii) Sole power to dispose or to direct the disposition of:
The information contained on the cover pages of this Schedule 13G is incorporated herein by reference.
(iv) Shared power to dispose or to direct the disposition of:
The information contained on the cover pages of this Schedule 13G is incorporated herein by reference.
Item 5.
Ownership of 5 Percent or Less of a Class.
Ownership of 5 percent or less of a class
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
Not Applicable
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.
Mr. Schneeberger is filing this Schedule 13G as a control person in respect of shares beneficially owned by ADAR1 Capital Management, an investment adviser as described in SS 240.13d-1(b)(1)(ii)(E).
Item 8.
Identification and Classification of Members of the Group.
Not Applicable
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
